Phone: (414) 918-9822    Email: [email protected]

Announcements

Stop-JIA Starts

By: CARRA | December 18, 2015 | CARRA Announcements, Registry Executive Committee, Research Committees, STOP-JIA

Start Time Optimization for Biologics in Polyarticular JIA, (STOP-JIA), funded by PCORI, is open for enrollment.  STOP-JIA is a comparative effectiveness study of the 3 CARRA poly JIA CTPs that differ on the timing of the initiation of biologics in new onset poly JIA:

STOP-JIA is a comparative effectiveness study of the 3 CARRA poly JIA CTPs that differ on the timing of the initiation of biologics in new onset poly JIA:

  • Step Up (methotrexate or another DMARD, then biologic if suboptimal response);
  • Early Combination (methotrexate/DMARD and biologic together at start); and
  • Biologic First (biologic, then methotrexate/DMARD or another biologic if suboptimal).

With a shared goal to enroll 400 patients over a 2-year period in as many CARRA Registry sites as possible, the STOP-JIA team asks that you complete both the training for the CARRA Registry and the STOP-JIA-specific training so we can rapidly start the study!

This is an important study that will provide insight into our understanding of which strategy will achieve the highest proportion of children with clinically inactive disease after 12 months of therapy.  In addition, information from patients and caregivers will be compared across the three comparative treatment plans giving us a better understanding of how patients feel and what they value as outcomes.  This information should inform our future choices of therapies.

An exciting feature of STOP-JIA is that we are employing iPads for completion of electronic PRO entry by patients directly into the registry database, eliminating the need for coordinators to collect and enter this data.  Each site will receive an iPad to facilitate electronic data entry by patients and caregivers while they are in clinic.  We know that one iPad may not be quite enough, and we are actively looking for funding to support additional iPads for each participating site.  In addition, in the coming months, iPads will also be used to be able to consent patients electronically for the CARRA Registry which will be a huge timesaver for sites.

The iPads will be provided with privacy screens, and will come equipped with Otter Boxes to avoid breakage.  There will be some helpful features programmed into the iPads about which you will learn during the short training session.  More news on training will come to you in the next weeks.

ClinicalTrials.gov identifier: NCT02593006